ElectroCore (Nasdaq:ECOR) announced today that it received patent issue notifications from the USPTO for three new patents.
All three — issued on April 11 — relate to ElectroCore’s non-invasive vagus nerve stimulation (nVNS) technology.
Rockaway, New Jersey-based ElectroCore received U.S. patents Nos. 11,623,078, 11,623,079 and 11,623,080.
The first (11,623,078) is titled “Devices and Methods for Non-Invasive Vagal Nerve Stimulation.” It generally relates to devices and methods for modulating the vagus nerve by transmitting an electrical impulse. This takes place transcutaneously through the neck of a patient. The electrical impulse comprises bursts of 2 to 20 pulses having a frequency of about 10 to 35 Hz.
ElectroCore’s second and third patents (11,623,079 and 11,623,080) fall under a similar umbrella. They are entitled “Vagal Nerve Stimulation Devices and Methods for Treating Medical Conditions” and “Vagal Nerve Stimulation for Dopamine-Related Conditions,” respectively.
These patents generally relate to nVNS devices and methods for treating addiction and other medical conditions. This includes releasing dopamine and/or endogenous opioids in the patient’s brain.
“ElectroCore continues to broaden its intellectual property portfolio, which consists of over 200 patents and patent applications,” said Dan Goldberger, CEO of ElectroCore. “We are focused on exploring ways in which nVNS can help treat a variety of disorders, such as addiction or other dopamine-related conditions, aside from our FDA-cleared use for primary headache.”
